Retatrutide 40mg & Cagrilintide 10mg
£240.90£300.00 (-20%)
The cagrilintide + retatrutide stack is a two-compound research protocol that pairs two of the most powerful weight-loss peptides in late-stage development. The plain-English version: retatrutide does the heavy lifting on appetite, blood sugar, and energy use.
The cagrilintide + retatrutide stack is a two-compound research protocol that pairs two of the most powerful weight-loss peptides in late-stage development. The plain-English version: retatrutide does the heavy lifting on appetite, blood sugar, and energy use. Cagrilintide adds a separate fullness signal that retatrutide does not hit on its own.
The idea behind this stack comes from Novo Nordisk’s CagriSema program. CagriSema combined cagrilintide with semaglutide (a single-receptor GLP-1 drug). In the Phase 3 REDEFINE-1 trial, adding cagrilintide to semaglutide pushed average weight loss from 14.9% to 20.4%. The reta + cag stack swaps semaglutide for retatrutide – which already hits three receptors – aiming to layer amylin satiety on top of broader metabolic effects.
What Each Compound Does
Retatrutide (LY3437943) is a triple agonist: GLP-1 (cuts appetite, slows the stomach), GIP (improves insulin signaling), and glucagon (raises energy use and fat burning). In Phase 3 TRIUMPH-4, retatrutide at 12 mg produced 28.7% body weight loss at 68 weeks vs 2.1% for placebo.
Cagrilintide is a long-acting amylin analog. Amylin is a hormone released by your pancreas after meals. It works in the hindbrain (a different part of the brain than GLP-1) to tell you that you have had enough food. Cagrilintide alone produced about 11.8% weight loss at 68 weeks in monotherapy and roughly 20.4% combined with semaglutide in REDEFINE-1.
Why People Pair Them
Retatrutide is powerful, but it does not activate amylin receptors. Cagrilintide fills that gap. The combined logic is:
- Two separate fullness channels. GLP-1 (reta) tells your gut to slow down. Amylin (cag) tells your hindbrain you are full. Different brain regions, different pathways.
- Stacked digestion slowdown. Both compounds slow gastric emptying. Food stays in the stomach longer, which extends fullness after meals.
- Four receptor pathways covered. GLP-1 (appetite) + GIP (insulin) + glucagon (energy burn) + amylin (fullness). No other current peptide stack covers this many pathways.
- CagriSema rationale extended. REDEFINE-1 showed that adding amylin to a GLP-1 backbone improves results. This stack tests the same logic with a triple-agonist backbone.
